Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6421 to 6435 of 8218 results

  1. Rituximab for aggressive non-Hodgkin's lymphoma (TA65)

    After consultation the guidance has been withdrawn because it is no longer relevant to clinical practice. Rituximab is now routinely used outside its licensed indication. See NICE’s guideline on non-Hodgkin’s lymphoma.

    Technology appraisal guidance
    Published
    24 September 2003

  2. Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer (TA831)

    This guidance has been updated and replaced by NICE technology appraisal guidance 887.

    Technology appraisal guidance
    Published
    5 October 2022

  3. The clinical effectiveness and cost effectiveness of technologies for the secondary prevention of osteoporotic fractures in postmenopausal women (TA87)

    This guidance has been updated and replaced NICE technology appraisal guidance 161.

    Technology appraisal guidance
    Published
    26 January 2005

  4. Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer (TA885)

    This guidance has been updated and replaced by NICE technology appraisal guidance 939.

    Technology appraisal guidance
    Published
    3 May 2023

  5. The use of autologous chondrocyte implantation for the treatment of cartilage defects in the knee joints (TA89)

    This guidance has been updated and replaced by NICE technology appraisal guidance 477. 

    Technology appraisal guidance
    Published
    25 May 2005

  6. Immunosuppressive therapy for renal transplantation in adults (TA85)

    This guidance has been updated and replaced by NICE technology appraisal guidance 481.

    Technology appraisal guidance
    Published
    22 September 2004

  7. Hearing disability - hearing aids (TA8)

    This guidance has been withdrawn.

    Technology appraisal guidance
    Published
    23 July 2000

  8. Clopidogrel in the treatment of non-ST-segment-elevation acute coronary syndrome (TA80)

    This guidance has been replaced by recommendations 1.3.4 to 1.3.8 in NICE guideline CG94 and by recommendation 1.3.18 in NICE guideline CG172.

    Technology appraisal guidance
    Published
    28 July 2004

  9. The clinical effectiveness and cost effectiveness of new drugs for bipolar disorder (TA66)

    This guidance has been updated and replaced NICE guideline CG38.

    Technology appraisal guidance
    Published
    24 September 2003

  10. Guidance on the use of photodynamic therapy for age-related macular degeneration (TA68)

    This guidance has been updated and replaced by NICE guideline NG82.

    Technology appraisal guidance
    Published
    24 September 2003

  11. Glitazones in the treatment of type 2 diabetes (TA63)

    This guidance has been updated and replaced by NICE guideline CG66 [partially updated by NICE guideline CG87]).

    Technology appraisal guidance
    Published
    27 August 2003

  12. Fremanezumab for preventing migraine (TA631)

    This guidance has been updated and replaced by NICE technology appraisal guidance 764.

    Technology appraisal guidance
    Published
    3 June 2020

  13. Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer (TA593)

    This guidance has been updated and replaced by NICE technology appraisal guidance 687.

    Technology appraisal guidance
    Published
    14 August 2019

  14. Taxanes for the treatment of breast cancer (TA6)

    This guidance has been replaced by NICE technology appraisal guidance 30 [Replaced by NICE guideline CG81].

    Technology appraisal guidance
    Published
    26 June 2000

  15. Guidance on the use of patient-education models for diabetes (TA60)

    This guidance has been replaced by NICE guideline NG17.

    Technology appraisal guidance
    Last updated
    1 August 2015